Research Stage • Building Innovation

Developing
Next-Gen BV Treatment

Developing a dissolvable, mucoadhesive vaginal film delivering standardized plant-derived antibiofilm compounds to eradicate BV pathogens while preserving beneficial Lactobacillus—a microbiome-friendly alternative to antibiotics.

Pre-Seed
Current Stage
Research
Product Development
2027
Target Clinical Trial

Seeking Strategic Partners & Advisors

Research Institutions
Industry Experts
Angel Investors
Biotech Mentors

BV Affects 1 in 3 Women

Current treatments fail to address the root cause, leading to recurrence rates above 50%

⚠️

Antibiotic Resistance

Traditional treatments contribute to growing antibiotic resistance, a global health crisis.

🔄

High Recurrence

Over 50% of women experience BV recurrence within 12 months of antibiotic treatment.

🦠

Biofilm Formation

Pathogenic bacteria form protective biofilms that resist conventional antibiotics.

Research-Driven Innovation

We're developing a mucoadhesive vaginal film that delivers standardized plant-derived compounds to disrupt biofilms while preserving beneficial Lactobacillus species.

Dissolvable Film Technology

Mucoadhesive matrix designed for extended vaginal residence time and controlled release.

Plant-Derived Compounds

Standardized botanical antibiofilm agents targeting pathogenic bacteria selectively.

Microbiome Preservation

Designed to eradicate pathogens while promoting beneficial Lactobacillus growth.

Development Targets

Target Efficacy 85%+
Biofilm Disruption Goal 90%+
Recurrence Target <20%

*Research phase development targets

How FemiShield Works

From application to action—see the complete mechanism of antibiofilm delivery

Plant-Derived
Biofilm Disruption
Microbiome-Friendly

The Journey

01

Simple Application

Discreet finger insertion—no applicator needed

02

Mucoadhesive Activation

Film adheres and dissolves, releasing compounds

03

Biofilm Disruption

Plant-derived agents target pathogenic matrix

04

Microbiome Restoration

Lactobacillus thrives as balance returns

Development Roadmap

Q1 2025 • Current
Formulation Development
Optimizing mucoadhesive polymer matrix
Q2-Q3 2025
In Vitro Testing
Antibiofilm efficacy studies
Q4 2025 - Q2 2026
Pre-Clinical Studies
Safety validation in models
Q3-Q4 2026
IND Preparation
Regulatory documentation
2027
Clinical Trials
Phase I/II human studies

Targeted Delivery

Mucoadhesive polymers ensure precise application

Natural Compounds

Standardized botanical antibiofilm agents

Controlled Release

Sustained therapeutic coverage

Low Irritancy

Microbiome-sparing formulation

Our Technology Platform

Combining pharmaceutical precision with botanical science

Smart Delivery System

Developing pH-responsive mucoadhesive polymers to maximize epithelial contact and drug residence time.

  • Controlled release kinetics
  • Moisture-activated dissolution
  • Extended therapeutic window

Bioactive Compounds

Researching standardized botanical extracts that work synergistically to disrupt biofilms and restore healthy vaginal flora.

  • Biofilm disruption mechanisms
  • Selective antimicrobial activity
  • Lactobacillus preservation

Why FemiShield

Non-Antibiotic

Avoiding antibiotic resistance concerns while targeting BV effectively.

Targeted Action

Designed to disrupt pathogenic biofilms while promoting beneficial flora.

Extended Release

Mucoadhesive delivery system for sustained therapeutic levels.

Plant-Derived

Natural compounds offering safety and efficacy without synthetic risks.

Research-Based

Developing evidence-based formulations with rigorous scientific validation.

Microbiome-Friendly

Preserving beneficial bacteria while eradicating pathogens.

Transforming Women's Health in Uganda

Reaching 10,000 women in 10 rural districts with affordable, effective BV treatment

🇺🇬
38-51%
BV prevalence in Uganda
🔄
60%
Recurrence within 6 months
💰
60-75%
Cost reduction target
👩
10,000
Women to benefit
❤️

Health Impact

Reduce 60% BV recurrence rate
Lower preterm birth risk 15-20%
Reduce 3.5x HIV risk
💵

Access & Affordability

UGX 5,000-8,000 target price
Self-administered treatment
No refrigeration needed
👥

Community Impact

Support 500+ farmers
Create 40-60 jobs at KPIL
Ugandan traditional medicine

Support Uganda Women's Health

Help us reach 10,000 women with affordable, effective treatment

Interested in Our Research?

We're seeking partners, advisors, and investors to help bring this innovative treatment to market. Contact us to learn more about collaboration opportunities.

Loading email service...